Journal Reviews

Rituximab as an immunosuppression treatment for thyroid eye disease

1 October 2015 | | Neuro-Ophthalmology | Biologic therapy, Graves disease, Graves orbitopathy, ophthalmopathy rituximab, thyroid-associated orbitopathy, thyroid eye disease

Thyroid eye disease is traditionally treated with high dose glucocorticosteroids and surgical orbital decompression, where responses are often inadequate. This medical treatment is centred around symptom control and reduction of thyroid hormone synthesis, not immunosuppression. Rituximab is an anti-CD20 monoclonal...